Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Intrinsic Value
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, engages in the development of cancer therapies. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SNDX.
Syndax Pharmaceuticals Inc's market capitalization is 1.8B USD.
SNDX stock price is 20.79 USD.
SNDX.
SNDX. Open DCF Valuation
SNDX. Open Relative Valuation
SNDX has upside potential of 73% compared to the average analyst price target.
Open Wall St Estimates
SNDX's ROE (Return on Equity) has significantly increased in the last 3 years from -61% to -41%, and is approaching profitability.
SNDX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 2 064% to -1 363%.
SNDX has negative Operating Income for the last twelve months.
SNDX has negative Net Income for the last twelve months.
SNDX's ROE (Return on Equity) for the past 12 months is negative and is equal to -41%.
SNDX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -1 363%.
SNDX has negative Free Cash Flow for the last twelve months.
SNDX has negative three-year average ROE (Return on Equity): -32%. The company is not efficient at transforming stockholders' equity into net income.
SNDX has negative three-year average ROIC (Return on Invested Capital): -1 846%. The company is not efficient at using invested capital to generate operating income.
SNDX's short-term assets (581m USD) exceed its short-term liabilties (58m USD).
SNDX's long-term assets (613m USD) exceed its long-term liabilties (59m USD).
SNDX has negative Net Debt. This means that the company has more cash and short-term investments (578m USD) than debt (10k USD).
SNDX's D/E (Debt to Equity) is very low and is equal to 0.
SNDX's Altman Z-Score is very high and is equal to 15.34.
Fundamental Analysis
Syndax Pharmaceuticals Inc
Balance Sheet Decomposition
Syndax Pharmaceuticals Inc
| Current Assets | 580.9m |
| Cash & Short-Term Investments | 577.6m |
| Receivables | 1.2m |
| Other Current Assets | 2.1m |
| Non-Current Assets | 32m |
| Long-Term Investments | 29.8m |
| PP&E | 1.5m |
| Other Non-Current Assets | 680k |
| Current Liabilities | 58.1m |
| Accounts Payable | 10m |
| Accrued Liabilities | 40.9m |
| Other Current Liabilities | 7.2m |
| Non-Current Liabilities | 588k |
| Long-Term Debt | 10k |
| Other Non-Current Liabilities | 578k |
Earnings Waterfall
Syndax Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-230m
USD
|
|
Operating Income
|
-230m
USD
|
|
Other Expenses
|
20.6m
USD
|
|
Net Income
|
-209.4m
USD
|
Free Cash Flow Analysis
Syndax Pharmaceuticals Inc
SNDX Profitability Score
Profitability Due Diligence
Syndax Pharmaceuticals Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Syndax Pharmaceuticals Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
SNDX Solvency Score
Solvency Due Diligence
Syndax Pharmaceuticals Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Score
Syndax Pharmaceuticals Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SNDX Price Targets Summary
Syndax Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
SNDX
is 35.98 USD
with a low forecast of 23.23 USD and a high forecast of 47.25 USD.
Ownership
SNDX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SNDX Price
Syndax Pharmaceuticals Inc
| Average Annual Return | 49.42% |
| Standard Deviation of Annual Returns | 71.21% |
| Max Drawdown | -61% |
| Market Capitalization | 1.8B USD |
| Shares Outstanding | 84 979 696 |
| Percentage of Shares Shorted | 11.41% |
Company Profile
Syndax Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, engages in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2016-03-03. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The firm is focused on developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1), protein for the treatment of MLL-rearranged (MLLr), acute leukemias and nucleophosmin 1 (NPM1), mutant acute myeloid leukemia (AML), as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative and breast cancer.
You don't have any saved screeners yet
